Navigation Links
New Actemra data shows significant benefit for patients suffering from rheumatoid arthritis
Date:11/8/2007

ent in haemoglobin levels. According to both studies, patients treated with Actemra plus DMARDs experienced greater improvements in quality of life and function measures, including fatigue and physical and mental functions compared to placebo plus DMARDs.

Actemra generally well tolerated in both TOWARD and OPTION

Actemra was generally well tolerated in both studies. The most common adverse events reported more frequently in the Actemra arm were upper respiratory tract infections, headache, nasopharyngitis and hypertension. As with other disease modifying anti-rheumatic drugs, serious infections have been reported in some patients treated with Actemra.

About Actemra

Actemra is the first humanised interleukin-6 (IL-6) receptor inhibiting monoclonal antibody and represents a novel mechanism of action to treat RA, a disease with a high unmet medical need. The overall safety profile observed in the global studies of Actemra is consistent and Actemra is generally well tolerated.

About rheumatoid arthritis

Rheumatoid arthritis is a progressive, systemic autoimmune disease characterized by chronic inflammation of multiple joints and fatigue as well as the possibility of osteoporosis, anaemia, and lung, skin and liver effects.


'/>"/>

Contact: Nicole Moores
nicole_moores@uk.cohnwolfe.com
44-020-733-15337
Cohn & Wolfe, London
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Research shows skeleton to be endocrine organ
2. Clones on task serve greater good, evolutionary study shows
3. Study shows link between alcohol consumption and hiv disease progression
4. Novel 3-D cell culture model shows selective tumor uptake of nanoparticles
5. New study shows greenback cutthroat trout involved in recovery effort misidentified
6. DNA analysis shows true dispersal of protozoa
7. New genetic research into nicotine addiction shows promise for personalized treatment
8. International team shows mercury concentrations in fish respond quickly to increased deposition
9. New study shows fish respond quickly to changes in mercury deposition
10. Amazon forest shows unexpected resiliency during drought
11. New study shows fish respond quickly to changes in mercury deposition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... protein, discovered in 2005, controls T-cell activation and ... In doing so, it helps to guarantee immunological ... own structures that can lead to autoimmune disease. ... affect between five and ten per cent of ... of complex environmental influences when a genetic predisposition ...
(Date:7/14/2014)... 140 years ago, Charles Darwin noticed something peculiar about ... are more tame, and they also tend to display ... patches of white fur, and more juvenile faces with ... pattern has proved elusive, but now, in a Perspectives ... new hypothesis has been proposed that could explain why ...
(Date:7/13/2014)... women suggests that experiencing one or more stressful events ... slow the body,s metabolism, potentially contributing to weight gain. ... stressors before giving them a meal consisting of 930 ... measured their metabolic rate how long it took ... took measures of blood sugar, triglycerides, insulin and the ...
Breaking Biology News(10 mins):Molecular mechanisms underlying the prevention of autoim-munity by Roquin revealed 2Domestication syndrome: White patches, baby faces and tameness 2Weighty issue: Stress and high-fat meals combine to slow metabolism in women 2Weighty issue: Stress and high-fat meals combine to slow metabolism in women 3Weighty issue: Stress and high-fat meals combine to slow metabolism in women 4
... Florida State University marine biologist David L. Kimbro will ... in a massive effort to study the health and ... estuaries spanning 1,000 miles of Atlantic and Gulf of ... June 1, has become even more vital now following ...
... fluent in English whose first language is Chinese retrieve their ... in the June 2 issue of The Journal of ... second language in adolescence or later recall the sounds of ... study, Yan Jing Wu, PhD, and Guillaume Thierry, PhD, of ...
... release is available in <A HREF=",http://chinese.eurekalert.org/zh/pub_releases/2010-06/sfeb-tio060110.php,">Chinese . ... of Medicine, in New Orleans, LA, have demonstrated ... seed oil ( Nigella sativa ) can suppress ... cell lines, in vitro. Although previous studies ...
Cached Biology News:Oil spill reshapes sweeping new study of oyster reefs -- Virginia to Florida 2Oil spill reshapes sweeping new study of oyster reefs -- Virginia to Florida 3Oil spill reshapes sweeping new study of oyster reefs -- Virginia to Florida 4Second language learners recall native language when reading 2Thymoquinone induced oxidative stress targets highly aggressive prostate cancers 2
(Date:7/11/2014)... , July 11, 2014 Research and ... Transfection Technology Market - Global Industry Analysis, Size, Share, ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... nucleic acids (either DNA or RNA) into cells. This ... of cancer cells and protein metabolism by affecting the ...
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/10/2014)... Ouagadougou, Burkina Faso (PRWEB) July 10, 2014 ... Burkina Faso, today have access to an additional ... to increase access to contraception at all levels ... combining a lower-dose formulation of a widely used ... injection system. , Burkina Faso is the first ...
(Date:7/10/2014)... 10, 2014 Understanding the need for ... lines, and the gap that currently exists in this ... its industry-leading portfolio of validated ion channel and GPCR ... cell lines, as ion channels control many critical physiological ... activity creates the potential to treat a variety of ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3
... Role of Chairman of the Board - , , ... INSM ), a biopharmaceutical company, today announced that Geoffrey Allan, ... Chairman of the Board of Directors, effective immediately, due to ... President, Chief Executive Officer and Chairman of the Board since ...
... , , , PHILADELPHIA, June 15 ERT ... and eClinical technology, ePRO, and other services to the biopharmaceutical, medical ... its portfolio of products and services at Booth #507 at the ... , , ERT will be showcasing, for the first ...
... returns to Paris for 2010 when, with ICSE, PMEC and BioPh, the ... on Tuesday 5 - Thursday 7 October. This is a week earlier ... to the dates of the last staging in Paris ... the quartet of co-located events to rival the 25,000+ attendees expected this ...
Cached Biology Technology:Insmed CEO Resigns Due to Health Concerns 2Insmed CEO Resigns Due to Health Concerns 3ERT to Showcase Its Clinical Trials Portfolio at DIA's 45th Annual Meeting at Booth #507 2ERT to Showcase Its Clinical Trials Portfolio at DIA's 45th Annual Meeting at Booth #507 3Paris Dates for CPhI Worldwide 2010 2